{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:49:05Z","timestamp":1793969345989,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.annonc.2025.09.017","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:06:06Z","timestamp":1760702766000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)"],"prefix":"10.1016","volume":"37","author":[{"given":"M.","family":"Roupret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-9509","authenticated-orcid":false,"given":"A.","family":"Bertaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-5754","authenticated-orcid":false,"given":"N.","family":"Houede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Corbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jaffrelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-2918","authenticated-orcid":false,"given":"C.","family":"Lebacle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2118","authenticated-orcid":false,"given":"S.","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lebdai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-O.","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-1341","authenticated-orcid":false,"given":"C.","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Goeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"Ju\u00e1rez Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"La","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"L\u00e9ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2025.09.017_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.017_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.09.017_bib3","series-title":"AJCC Cancer Staging Manual","first-page":"757","year":"2017"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.017_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.017_bib5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.017_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.36469\/jheor.2024.124208","article-title":"Adherence to first-line intravesical bacillus Calmette-Gu\u00e9rin therapy in the context of guideline recommendations for US patients with high-risk non-muscle invasive bladder cancer","volume":"11","author":"Gaylis","year":"2024","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.017_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12894-025-01734-6","article-title":"Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Gu\u00e9rin) therapy: a retrospective observational study","volume":"25","author":"Aksakalli","year":"2025","journal-title":"BMC Urol"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.017_bib8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.21037\/apm-22-1350","article-title":"Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence","volume":"12","author":"Uccello","year":"2023","journal-title":"Ann Palliat Med"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.017_bib9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.017_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/2326-6066.CIR-15-0176","article-title":"Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor","volume":"4","author":"Vandeveer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.annonc.2025.09.017_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urolonc.2023.10.004","article-title":"Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: the evolving role of PD-(L)1 inhibition","volume":"41","author":"Bedke","year":"2023","journal-title":"Urol Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.09.017_bib12","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.017_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without Bacille Calmette-Gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.annonc.2025.09.017_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1200\/JCO.2024.42.4_suppl.595","article-title":"BladderGATE: atezolizumab + intravesical BCG (bacillus Calmette-Guerin) upfront combination in patients with high risk non-muscle invasive bladder cancer (NMIBC)\u2014phase I-II ONCOSUR study","volume":"42","author":"Castellano","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2025.09.017_bib15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.017_bib16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.017_bib17","article-title":"Outcomes of BCG induction in high-risk non-muscle-invasive bladder cancer patients (NMIBC): a retrospective cohort study","volume":"9","author":"Pirzada","year":"2017","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.017_bib18","doi-asserted-by":"crossref","first-page":"391.e1","DOI":"10.1016\/j.urolonc.2025.01.015","article-title":"Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure","volume":"43","author":"Gerald","year":"2025","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.017_bib19","article-title":"A0731 \u2013 First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab + intravesical bacillus Calmette-Gu\u00e9rin (BCG) upfront combination in BCG-na\u00efve high risk non-muscle invasive bladder cancer patients","volume":"85","author":"Guerrero-Ramos","year":"2024","journal-title":"Eur Urol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425047878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425047878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:02:28Z","timestamp":1773856948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425047878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0923753425047878"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}